ArticleActa neurologica Belgica2021
Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report.
Article in Acta neurologica Belgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between Galectin Levels and Neurodegenerative Diseases: Systematic Review and Meta-Analysis.Biomolecules · 2022Pooled it
- Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation-A Narrative Review.International journal of molecular sciences · 2026Review
- Pleiotropic regulatory mechanisms and targeted therapeutic prospects of Galectin-3 in aging-related diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Exploration and validation of the immune-related genes signatures and potential molecular mechanisms shared between Alzheimer's disease (AD) and Parkinson's disease (PD).BMC medical genomics · 2025Article
- Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.Molecular neurodegeneration · 2025Review
- Senescence accelerated mouse-prone 8: a model of neuroinflammation and aging with features of sporadic Alzheimer's disease.Stem cells (Dayton, Ohio) · 2025Review
- Music elicits different gene expression responses in the buccal cavity of age-related cognitive disorders patients and healthy controls.Frontiers in aging neuroscience · 2025Article
- Farnesylthiosalicylic Acid Through Inhibition of Galectin-3 Improves Neuroinflammation in Alzheimer Disease via Multiple Pathways.CNS neuroscience & therapeutics · 2024Article
- The Role ofJournal of clinical medicine · 2024Review
- Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Exploring galectin-3's role in predicting mild cognitive impairment in type 2 diabetes and its regulation by miRNAs.Frontiers in medicine · 2024Article
- Towards early diagnosis of Alzheimer's disease: advances in immune-related blood biomarkers and computational approaches.Frontiers in immunology · 2024Review
- Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?Frontiers in pharmacology · 2023Review
- The Anxiolytic Activity ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer's disease.Acta neuropathologica · 2022Article
- Cross-Talk and Subset Control of Microglia and Associated Myeloid Cells in Neurological Disorders.Cells · 2022Review
- Neuroinflammation and galectins: a key relationship in neurodegenerative diseases.Glycoconjugate journal · 2022Review
- Galectins-Potential Therapeutic Targets for Neurodegenerative Disorders.International journal of molecular sciences · 2022Review
- Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration.Cell death & disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsNeuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer's disease (AD).
methodsThis was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls.
resultsIn our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience's age, and duration of disease were statically and significantly increased (p < 0.05).
conclusionIn conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.
Indexed as
Identifiers
32852752What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.